Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management

Table 2

Recommendations for monitoring and reversal of NOACs.

NOAC	Trial name	Most accurate monitoring tests	Qualitative monitoring tests	Reversal
Dabigatran	RE-LY	HTI; ECT	TT; aPTT	(i) Activated charcoal (if a recent ingestion has been reported); (ii) FEIBA (activated PCC); (iii) Hemodialysis; (iv) aDabi-Fab idarucizumab]^*; (v) PER977^*
Rivaroxaban	ROCKET AF	Antifactor Xa chromogenic assays	PT	(i) Recombinant activated factor VII (rFVIIa); (ii) Co-fact© (a nonactivated PCC); (iii) FEIBA (activated PCC); (iv) Andexanet alfa (PRT4445) (ANNEXA-R)^*; (v) PER977^*
Apixaban	AVERROES; ARISTOTLE
Edoxaban	ENGAGE AF-TIMI

Those reversal agents are still under evaluation.